The U.S. Patent and Trademark Office (USPTO) has granted Canada-based psychedelics company Cybin Inc. (NYSE: CYBN) a new patent covering the composition of matter of deuterated 5-MeO-DMT analogs and their pharmaceutical compositions with exclusivity until 2041. 

Considering the recently granted patent covering its clinically advanced compounds psilocybin analog CYB003 and DMT analog CYB004 as well as its announced intention to acquire U.K. short-acting psychedelics developer Small Pharma (OTCMKTS: DMTTF), Cybin rightly claims the new grant strengthens its forefront position within the development of “potential, best-in-class deuterated, tryptamine-based therapeutics for the treatment of mental health conditions.”

See Also: Treating …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.